Abstract

Background

Tau pathology plays a crucial role in neurodegeneration diseases including Alzheimer’s disease (AD) and non-AD diseases such as progressive supranuclear palsy. Tau positron emission tomography (PET) is an in-vivo and non-invasive medical imaging technique for detecting and visualizing tau deposition within a human brain. In this work, we aim to investigate the biodistribution of the dosimetry in the whole body and various organs for the [18F]Florzolotau tau-PET tracer. A total of 12 healthy controls (HCs) were enrolled at Chang Gung Memorial Hospital. All subjects were injected with approximately 379.03 ± 7.03 MBq of [18F]Florzolotau intravenously, and a whole-body PET/CT scan was performed for each subject. For image processing, the VOI for each organ was delineated manually by using the PMOD 3.7 software. Then, the time-activity curve of each organ was acquired by optimally fitting an exponential uptake and clearance model using the least squares method implemented in OLINDA/EXM 2.1 software. The absorbed dose for each target organ and the effective dose were finally calculated.

Results

From the biodistribution results, the elimination of [18F]Florzolotau is observed mainly from the liver to the intestine and partially through the kidneys. The highest organ-absorbed dose occurred in the right colon wall (255.83 μSv/MBq), and then in the small intestine (218.67 μSv/MBq), gallbladder wall (151.42 μSv/MBq), left colon wall (93.31 μSv/MBq), and liver (84.15 μSv/MBq). Based on the ICRP103, the final computed effective dose was 34.9 μSv/MBq with CV of 10.07%.

Conclusions

The biodistribution study of [18F]Florzolotau demonstrated that the excretion of [18F]Florzolotau are mainly through the hepatobiliary and gastrointestinal pathways. Therefore, a routine injection of 370 MBq or 185 MBq of [18F]Florzolotau leads to an estimated effective dose of 12.92 or 6.46 mSv, and as a result, the radiation exposure to the whole-body and each organ remains within acceptable limits and adheres to established constraints.

Trial registration

Retrospectively Registered at Clinicaltrials.gov (NCT03625128) on 12 July, 2018, https://clinicaltrials.gov/study/NCT03625128.

Details

Title
Human biodistribution and radiation dosimetry for the tau tracer [18F]Florzolotau in healthy subjects
Author
Lin, Kun-Ju 1 ; Huang, Shao-Yi 2 ; Huang, Kuo-Lun 3 ; Huang, Chin-Chang 3 ; Hsiao, Ing-Tsung 1   VIAFID ORCID Logo 

1  Chang Gung Memorial Hospital, Department of Nuclear Medicine, Linkou, Taiwan (GRID:grid.413801.f) (ISNI:0000 0001 0711 0593); Chang Gung University, Department of Medical Imaging and Radiological Sciences and Healthy Aging Research Center, Taoyuan City, Taiwan (GRID:grid.145695.a) (ISNI:0000 0004 1798 0922) 
2  Chang Gung University, Department of Medical Imaging and Radiological Sciences and Healthy Aging Research Center, Taoyuan City, Taiwan (GRID:grid.145695.a) (ISNI:0000 0004 1798 0922) 
3  Chang Gung Memorial Hospital, Department of Neurology, Linkou, Taiwan (GRID:grid.413801.f) (ISNI:0000 0001 0711 0593) 
Pages
27
Publication year
2024
Publication date
Dec 2024
Publisher
Springer Nature B.V.
e-ISSN
2365-421X
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1186/s41181-024-00259-x
ProQuest document ID
3030967098
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.